Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The information required by this Item will be set forth in the section headed “Executive Compensation” in the Proxy Statement to be filed with the SEC within 120 days after the Company’s fiscal year end and is incorporated herein by reference.
The information required by Item 402(x) of Regulation S-K shall be set forth in the section headed “Policies and Practices Related To The Grant Of Certain Equity Awards Close In Time To The Release Of Material Nonpublic Information” in the Proxy Statement and is incorporated in this report by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.